Dr. Weyrich's Naturopathic Functional Medicine Notebook is a collection of information on topics of interest
to Dr. Weyrich that may be of interest to the world wide audience.
Due to limitations of time, not all information that Dr. Weyrich knows or would like to further research is
Dr. Weyrich welcomes financial contributions to support specific research topics, as well as copies of
non-free access journal articles for him to review on a topic.
Constructive criticism is also welcome.
Please see Cancer Overview for general information that is common to all forms of cancer.
Dr. Weyrich is not an expert in the treatment of cancer, but does offer supportive
therapies to reduce pain and nausea, mitigate the side effects, and to generally boost the immune system.
Complimentary and alternative treatments for ovarian cancer that are considered below include:
Low Dose Naltrexone
Etiology of Ovarian Cancer
[Friedman2013] has presented a compelling model for the prevention and treatment of breast and prostate cancer.
An important feature of this model is observation that synthetic (non-bio-identical) estrogens and progestins actually
raise the risk of breast and prostate cancer. On the other hand, it appears
[Hankinson1992], [CDC1987], [Schildkraut2002] that synthetic estrogens do not affect
ovarian cancer, and synthetic progestins actually reduce the incidence of ovarian cancer by up to 50%.
Synthetic progestins have also been found
by some [Narod1998], [Antoniou2009], but not all [Modan2001],
studies to be protective against ovarian cancer in women with BRCA-1 or BRCA-2 mutations.
Dr. Weyrich notes that Mifepristone (RU-486) (FDA-approved as a "morning-after" abortifacient) is antagonistic to Progesterone Receptor-Alpha, and has been
shown to reduce levels of the tumor-promoting protein bcl-2 in BRCA-1/BRCA-2 mutation-positive individuals. Dr. Weyrich speculates that a similar
mechanism might be exerted by other synthetic progestins in the case of ovarian cancer.
The differences between different types of cancers require further study.
Naturopathic, Complimentary and Alternative Treatments
Low Dose Naltrexone (LDN)
[LDN_Cancer] reports that the late Dr. Bernard Bihari treated approximately 450
patients with some form of cancer, with a 60% success rate, almost all of who had failed to
respond to standard treatments.
In particular, 4 patients with ovarian cancer appeared to be in remission.
In one case, a patient with treatment-resistant ovarian cancer appeared to be in remission
after 3 months of LDN treatment, but after another 11 months, suffered a relapse and passed
away four months thereafter, despite continuing the LDN.
[ORWJr: LDN is not a panacea, although it may buy a patient a significant amount of
"quality time". Concurrent treatment with progesterone or progestins may have extended the
Dr. Weyrich has been trained in the use of Low Dose Naltrexone (LDN).
However, Dr. Weyrich has not treated any cases of ovarian cancer with LDN.